Synergistic Antitumor Effect of α-pinene and β-pinene with Paclitaxel against Non-small-cell Lung Carcinoma (NSCLC)

Abstract

The objective of the present research work was to evaluate the synergistic interactions between Paclitaxel (PAC) with α-pinene and β-pinene using isobolographic method against non-small-cell lung cancer cells (NSCLC). This type of interaction between an established drug and a new compound is expected to enhance the efficacy of paclitaxel in combination as compared in isolation. Further, cell cycle analysis was carried out using flow cytometric analysis. Phase contrast microscopy was used to assess the effect of paclitaxel, α-pinene and β-pinene alone and in combination with each other in order to evaluate the effect of combination on cell apoptosis. Further, mitochondrial membrane potential was monitored in non-small-cell lung cancer cells (NSCLC) when treated with paclitaxel, α-pinene and β-pinene alone and in combination. The results revealed that the combination of PAC with α-pinene or with β-pinene showed a plotted curve below the straight line, generating a substantial synergistic effect. The effects of the following combinations were examined utilizing isobolograms: PAC and α-pinene and PAC and β-pinene. The combination of PAC and α-pinene as well as of PAC and β-pinene actually generated a synergistic effect. We also examined the effects of these compounds on the cell cycle distributions of A549 cells by flow cytometric analysis. The percentage of sub-G0/G1-phase cells was decreased on the addition of α-pinene to PAC, while the population of G0/G1 cells was increased. The morphological changes characteristic of apoptosis like chromatin condensation and fragmentation of the nucleus were seen in PAC+α-pinene and PAC+β-pinene treated NSCLC cells.

Key words

paclitaxel - non-small-cell lung cancer - synergy - α-pinene - anticancer activity

• References

• 1 Alberg AJ, Brock MV, Stuart JM. Epidemiology of lung cancer: Looking to the future. Journal of Clinical Oncology 2005; 23: 3175-3185
• 2 American Cancer Society . Cancer Facts & Figures 2014. Atlanta, Ga: American Cancer Society; 2014
• 3 Posther KE, Harpole DH. The surgical management of lung cancer. Cancer Investigation 2006; 24: 56-67
• 4 Quoix E, Ramlau R, Westeel V et al. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: A controlled phase 2B trial. The Lancet Oncology 2011; 12: 1125-1133
• 5 Huang GJ, Fang DK, Cheng GY et al. Surgical therapeutic strategy for non-small cell lung cancer with (N2) mediastinal lymph node metastasis. Zhonghua Zhong Liu Za Zhi 2006; 28: 62-64
• 6 Li Y, Li H, Hu Y et al. Clinical study of lymph node metastasis in lung cancer. Chinese Journal of Thoracic Cardiovascular Surgery 2000; 16: 10-12
• 7 Ukena D. Chemotherapy in stage I+II non-small cell lung cancer. Lung Cancer 2001; 33: S25-S28
• 8 Waller DA. Neoadjuvant chemotherapy in non small cell lung cancer – the UK experience. Lung Cancer 2001; 34: S31-S33
• 9 Azim HA, Ganti AK. Treatment options for relapsed small-cell lung cancer. Anticancer drugs 2007; 18: 255-261
• 10 MacCallum C, Gillenwater HH. Second-line treatment of small-cell lung cancer. Current Oncology Reports 2006; 8: 258-264
• 11 Eid SY, El-Readi MZ, Wink M. Carotenoids reverse multidrug resistance in cancer cells by interfering with ABC-transporters. Phytomedicine 2012; 19: 977-987
• 12 Bardon S, Picard K, Martel P. Monoterpenes inhibit cell growth, cell cycle progression, and cyclin D1 gene expression in human breast cancer cell lines. Nutrition Cancer 1998; 32: 1-7
• 13 Gómez-Contreras PC, Hernández-Flores G, Ortiz-Lazareno PC et al. In vitro induction of apoptosis in U937 cells by perillyl alcohol with sensitization by pentoxifylline: Increased Bcl-2 and Bax protein expression. Chemotherapy 2006; 52: 308-315
• 14 Rotem R, Heyfets A, Fingrut O et al. Jasmonates: novel anticancer agents acting directly and selectively on human cancer cell mitochondria. Cancer Research 2005; 65: 1984-1993
• 15 Wang W, Wu N, Zu YG et al. Antioxidative activity of Rosmarinus officinalis L. essential oil compared to its main components. Food Chemistry 2008; 108: 1019-1022
• 16 Cock IE. The phytochemistry and chemotherapeutic potential of Tasmannia lanceolata (Tasmanian pepper): A review. Pharmacognosy Communications 2013; 3
• 17 Elanur A, Hasan T, Fatime G. Antioxidative, anticancer and genotoxic properties of α-pinene on N2a neuroblastoma cells. Biologia 2013; 68: 1004-1009
• 18 Jordan MA, Toso RJ, Thrower D et al. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proceeding of the National Academy of Sciences of the United States of America 1993; 90: 9552-9556
• 19 Milross CG, Mason KA, Hunter NR et al. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. Journal of the National Cancer Institute 1996; 88: 1308-1314
• 20 Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nature Reviews Cancer 2004; 4: 253-265
• 21 Rodriguez-Antona C. Pharmacogenomics of paclitaxel. Pharmacogenomics 2010; 11: 621-623
• 22 Gottesman MM. Mechanisms of cancer drug resistance. Annual Review of Medicine 2002; 53: 615-627
• 23 Aoki D, Oda Y, Hattori S et al. Overexpression of class III beta-tubulin predicts good response to taxane-based chemotherapy in ovarian clear cell adenocarcinoma. Clinical Cancer Research 2009; 15: 1473-1480
• 24 Qi Y, Fu X, Xiong Z et al. Methylseleninic acid enhances paclitaxel efficacy for the treatment of triple-negative breast cancer. PLoS One 2012; 7: e31539
• 25 Le XF, Mao W, He G et al. The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells. Journal of the National Cancer Institute 2011; 103: 1403-1422